Adaptimmune Therapeutics PLC (NASDAQ:ADAP)‘s stock had its “buy” rating reiterated by analysts at SunTrust Banks, Inc. in a research report issued to clients and investors on Thursday. They presently have a $10.00 target price on the biotechnology company’s stock. SunTrust Banks, Inc.’s price target indicates a potential upside of 28.87% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on ADAP. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 8th. Zacks Investment Research raised shares of Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Wednesday, July 12th. ValuEngine raised shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 20th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $15.00 price target on shares of Adaptimmune Therapeutics PLC in a research report on Friday, September 8th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $11.58.

Shares of Adaptimmune Therapeutics PLC (ADAP) traded down 1.02% during trading on Thursday, hitting $7.76. 256,152 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $8.41 and a 200-day moving average price of $8.41. Adaptimmune Therapeutics PLC has a one year low of $3.76 and a one year high of $9.29. The stock’s market cap is $725.71 million.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share for the quarter, hitting the consensus estimate of ($0.24). Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. The firm had revenue of $3.52 million during the quarter, compared to analysts’ expectations of $5.43 million. Equities research analysts expect that Adaptimmune Therapeutics PLC will post ($0.99) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/12/adaptimmune-therapeutics-plc-adap-receives-buy-rating-from-suntrust-banks-inc.html.

A number of large investors have recently bought and sold shares of the stock. NEA Management Company LLC lifted its position in Adaptimmune Therapeutics PLC by 21.7% during the first quarter. NEA Management Company LLC now owns 12,025,999 shares of the biotechnology company’s stock valued at $66,263,000 after acquiring an additional 2,145,000 shares during the last quarter. Matrix Capital Management Company LP purchased a new stake in Adaptimmune Therapeutics PLC during the second quarter valued at approximately $39,027,000. Capital World Investors lifted its position in Adaptimmune Therapeutics PLC by 168.4% during the fourth quarter. Capital World Investors now owns 4,601,000 shares of the biotechnology company’s stock valued at $55,488,000 after acquiring an additional 2,887,082 shares during the last quarter. Tekla Capital Management LLC lifted its position in Adaptimmune Therapeutics PLC by 158.9% during the first quarter. Tekla Capital Management LLC now owns 1,466,368 shares of the biotechnology company’s stock valued at $8,080,000 after acquiring an additional 900,000 shares during the last quarter. Finally, Baillie Gifford & Co. lifted its position in Adaptimmune Therapeutics PLC by 43.7% during the second quarter. Baillie Gifford & Co. now owns 1,323,308 shares of the biotechnology company’s stock valued at $5,941,000 after acquiring an additional 402,324 shares during the last quarter. 68.01% of the stock is owned by institutional investors.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Analyst Recommendations for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.